Santarus loads up on sales reps

Share this article:
Drug maker Santarus is bringing on 85 reps ahead of the launch of its ulcerative colitis drug Uceris.

The new hires are a mix of contract reps sourced from InVentiv Health and full-time Santarus reps. They will bring the launch force to 235 reps, along with 10 staff medical science liaisons. The company expects to connect with between 7,000 and 8,000 healthcare professionals, including rep-resistant primary care physicians along with endocrinologists. All will receive the same presentation -- CEO Gerry Proehl told MM&M that all reps, be they contract or in-house Santarus, have the same sales goals and pay incentives, and that all report to Santarus managers. The reason he gave was a simple one: all physicians should have a seamless experience.

What doctors should expect: iPad-equipped sales professionals with eight to ten years of pharmaceutical experience under their belts and leave-behinds by healthcare agency Harrison and Starr, which also handled some of the patient work.

Yet the pitch is not just about the drug's immediate target, of helping patients mid-flare-up. It also includes a pricing approach that aims to be in the managed care comfort zone. Proehl said the $1,235 for a month's supply is slightly below that of AstraZeneca's Entocort for Crohn's disease (the Santarus drug has a different indication, for ulcerative colitis). According to doctors Santarus has been talking to, the target patients – those in mid-flare – have symptoms between two to four times a year, but seek treatment about once or twice a year. The typical eight-week therapy would bring a patient's bill for the treatment to just under $5,000.

And although the drug is not yet on insurer formularies – the FDA approved it in January, long after formularies were set for the year – Proehl said that the drug is on insurers' minds, and that the company has been told that Uceris is being viewed as an interim drug patients can use before progressing to more expensive options, which can include higher-cost biologics or surgery. Proehl said he expects the drug to linger in the Tier 3 realm and possibly be tagged with a prior authorization requirement for the time being.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?